Clinical Utility of Metrics Based on Tumor Measurements in Phase II Trials to Predict Overall Survival Outcomes in Phase III Trials by Using Resampling Methods

類似資料

• Evaluating Continuous Tumor Measurement-Based Metrics as Phase II Endpoints for Predicting Overall Survival
  著者:: An, Ming-Wen, 等
  出版事項: (2015)
• Evaluation of Alternate Categorical Tumor Metrics and Cut Points for Response Categorization Using the RECIST 1.1 Data Warehouse
  著者:: Mandrekar, Sumithra J., 等
  出版事項: (2014)
• Comparison of continuous versus categorical tumor measurement-based metrics to predict overall survival in cancer treatment trials
  著者:: An, Ming-Wen, 等
  出版事項: (2011)
• A Review of Phase II Trial Designs for Initial Marker Validation
  著者:: Mandrekar, Sumithra J., 等
  出版事項: (2013)
• Randomized Phase II Trials: Time for a New Era in Clinical Trial Design
  著者:: Mandrekar, Sumithra J., 等
  出版事項: (2010)